Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021-June 2022

Ryan Sandford; Ruchi Yadav; Emma K Noble; Kelsey Sumner; Devyani Joshi; Sara Y Tartof; Karen J Wernli; Emily T Martin; Manjusha Gaglani; Richard K Zimmerman; H Keipp Talbot; Carlos G Grijalva; Edward A Belongia; Christina Carlson; Melissa Coughlin; Brendan Flannery; Brad Pearce; Eric Rogier

doi:10.1101/2023.11.17.23298700

Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021-June 2022

medRxiv [Preprint]. 2023 Nov 18:2023.11.17.23298700. doi: 10.1101/2023.11.17.23298700.

Authors

Ryan Sandford^{1

2

3}, Ruchi Yadav¹, Emma K Noble^{1

2}, Kelsey Sumner¹, Devyani Joshi¹, Sara Y Tartof^{4

5}, Karen J Wernli⁶, Emily T Martin⁷, Manjusha Gaglani^{8

9}, Richard K Zimmerman¹⁰, H Keipp Talbot¹¹, Carlos G Grijalva¹¹, Edward A Belongia¹², Christina Carlson¹, Melissa Coughlin¹, Brendan Flannery¹, Brad Pearce³, Eric Rogier¹

Affiliations

¹ Centers for Disease Control and Prevention, Atlanta, GA, USA.
² Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA.
³ Rollins School of Public Health, Atlanta, GA, USA.
⁴ Kaiser Permanente Southern California, Department of Research & Evaluation.
⁵ Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
⁶ Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
⁷ University of Michigan School of Public Health, Ann Arbor, MI, USA.
⁸ Baylor Scott & White Health, Temple, TX, USA.
⁹ Texas A&M University College of Medicine, Temple, TX, USA.
¹⁰ University of Pittsburgh, Pittsburgh, PA, USA.
¹¹ Vanderbilt University Medical Center, Nashville, TN, USA.
¹² Marshfield Clinic Research Institute, Marshfield, WI, USA.

Abstract

To describe humoral immune responses to symptomatic SARS-CoV-2 infection, we assessed immunoglobulin G binding antibody levels using a commercial multiplex bead assay against SARS-CoV-2 ancestral spike protein receptor binding domain (RBD) and nucleocapsid protein (N). We measured binding antibody units per mL (BAU/mL) during acute illness within 5 days of illness onset and during convalescence in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 infection with Omicron variant viruses. Comparing acute- to convalescent phase antibody concentrations, geometric mean anti-N antibody concentrations increased 47-fold from 5.5 to 259 BAU/mL. Anti-RBD antibody concentrations increased 2.5-fold from 1258 to 3189 BAU/mL.

Keywords: COVID-19; SARS-CoV-2 infection; immune response; omicron subvariants.

Publication types

Preprint

Abstract

Publication types

Grants and funding